论文部分内容阅读
目的观察普罗布考和辛伐他汀分别治疗糖尿病性动脉硬化伴多发斑块形成的临床疗效比较。方法将120例2型糖尿病并发动脉硬化伴多发斑块形成的患者随机分成普罗布考治疗组和辛伐他汀治疗组。在应用普罗布考和辛伐他汀治疗的同时需保障患者的血糖、血压平稳。通过对两组进行3个月的治疗,两组病例均于治疗3个月后观察多普勒超声及化验室各项生化指标(血总胆固醇、LDL胆固醇、HDK胆固醇、甘油三酯、C反应蛋白),进行各组治疗前和治疗后比较,以及两组间各项指标进行比较。结果各组在治疗3个月后,患者的双颈部动脉和双下肢动脉多普勒超声示斑块均有明显减少甚至消失的较好疗效,值得推广。检验血脂的各项指标基本恢复正常,CRP也明显恢复正常。但在两组间进行比较,普罗布考治疗组的各项指标恢复程度明显优于辛伐他汀治疗组。结论普罗布考通过抑制低密度脂蛋白的合成、促进其降解,有效降低低密度脂蛋白胆固醇水平,它还有抗氧化剂作用,抗氧化应激可以减轻血管内皮损伤,减少动脉斑块形成并缩小已经形成的斑块,对治疗糖尿病性动脉病变比辛伐他汀有意义。
Objective To observe the clinical efficacy of probucol and simvastatin in the treatment of diabetic arteriosclerosis with multiple plaques. Methods 120 patients with type 2 diabetes complicated with atherosclerosis and multiple plaque formation were randomly divided into probucol treatment group and simvastatin treatment group. In the application of probucol and simvastatin treatment at the same time to protect the patient’s blood sugar, blood pressure and stability. After three months treatment, the two groups were observed Doppler ultrasound and laboratory biochemical indicators (blood total cholesterol, LDL cholesterol, HDK cholesterol, triglyceride, C reaction Protein), compared before and after treatment in each group, as well as the indicators between the two groups were compared. Results After 3 months of treatment, both groups had obvious curative effect of reducing or even disappearing both double-neck artery and double-lower extremity arterial Doppler ultrasound, which is worth to be popularized. The indicators of blood lipids returned to normal, CRP also returned to normal. However, in comparison between the two groups, the indicators of probucol treatment group were significantly better than the simvastatin treatment group. Conclusions Probucol can inhibit the synthesis of low density lipoprotein, promote its degradation and effectively reduce the level of low density lipoprotein cholesterol. It also has anti-oxidant effect. Antioxidant stress can reduce vascular endothelial injury, reduce plaque formation and reduce Already formed plaques are more meaningful than simvastatin in the treatment of diabetic arterial lesions.